Lexaria Bioscience Corp. announced on April 28, 2025, the closing of its previously announced registered direct offering. The company sold 2,000,000 shares of common stock, or pre-funded warrants in lieu thereof, at a purchase price of $1.00 per share.
The gross proceeds to the company from the offering were $2.0 million, before deducting placement agent fees and other offering expenses. Lexaria intends to use the net proceeds for working capital and other general corporate purposes.
This capital raise provides Lexaria with necessary funds to support its ongoing research and development initiatives. However, the issuance of new shares at this price point results in dilution for existing shareholders.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.